儿童寻常型天疱疮经利妥昔单抗治疗后痊愈。
Childhood pemphigus vulgaris successfully treated with rituximab.
机构信息
Department of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Indian J Dermatol Venereol Leprol. 2012 Sep-Oct;78(5):632-4. doi: 10.4103/0378-6323.100587.
Pemphigus is a potentially fatal autoimmune epidermal bullous disorder. Rituximab is a novel therapy for the treatment of refractory pemphigus. However, there is limited clinical data on safety and efficacy of rituximab in pediatric age group. Herein, we report an 11-year-old boy of childhood pemphigus vulgaris who failed to respond to dexamethasone pulse therapy and was subsequently treated with rituximab and achieved complete remission.
天疱疮是一种潜在致命的自身免疫性表皮大疱病。利妥昔单抗是治疗难治性天疱疮的一种新疗法。然而，关于利妥昔单抗在儿科年龄组中的安全性和疗效的临床数据有限。在此，我们报告一例 11 岁儿童寻常型天疱疮患儿，他对地塞米松脉冲治疗无反应，随后用利妥昔单抗治疗并获得完全缓解。
Zotero 插件